ImmunoCellular Therapeutics IMUC
announced the expansion of its relationship with Progenitor Cell
Therapy, LLC (“PCT”), a subsidiary of NeoStem, Inc. NBS, for
current good manufacturing practices (cGMP) services for
ImmunoCellular's dendritic cell-based vaccines. PCT currently
manufactures ICT-121, a dendritic cell vaccine targeting CD133 cells, in
a phase I clinical trial for recurrent glioblastoma multiforme (GBM)
pursuant to a Services Agreement between the companies. PCT also
manufactured phase II clinical supplies of ICT-107, a dendritic
cell-based vaccine targeting six tumor-associated antigens for newly
diagnosed GBM. Under this newly executed Services Agreement, PCT will
manufacture clinical supplies of ICT-140, a dendritic cell vaccine
targeting seven ovarian cancer antigens, using process improvements PCT
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in